Ovid Starts Neurology Spree With AstraZeneca Deal

The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.

Epilepsy brain
Ovid announced an in-licensing deal with AstraZeneca for a library of KCC2 transporter-targeting drugs • Source: Shutterstock

Ovid Therapeutics, Inc. is kicking off the new year with a multimillion-dollar licensing deal with AstraZeneca PLC that Ovid CEO Jeremy Levin said is one component of a broader development strategy in neurology, which it is financing with the help of an out-licensing agreement in early 2021 with Takeda Pharmaceutical Co. Ltd.

The company said on 3 January that it had licensed from AstraZeneca a library of early-stage small molecule drugs that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?